Chronic Hepatitis B Virus Infection and Risk of Pancreatic Cancer: A Meta-analysis

Li, Lei; Wu, Bo; Yang, Libo; Yin, Guancheng; Liu, Jiyong

doi:10.7314/apjcp.2013.14.1.275

Cited by 25 publications

(15 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Other risk factors that have been mentioned sporadically in worldwide literature, Included: Drinking alcohol, family history, blood group (p<0.01), HCV (p<0.01), HBV infection can cause about 40.7% increase in the risk of pancreatic cancer (Matsuo et al, 2011;Engin et al, 2012;Lei et al, 2013;Woo et al, 2013). Trace elements significant increase (p<0.0001) in blood Cd in PC patients compared with controls (Farzin et al, 2013).…”

Section: Discussionmentioning

confidence: 99%

Clinical, Laboratory Biomarkers and Imaging Findings of Pancreatic Adenocarcinoma in Iran

Hadizadeh

Padashi²,

Alizadeh³

et al. 2014

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Clinical, Laboratory Biomarkers and Imaging Findings of Pancreatic Adenocarcinoma in Iran

Hadizadeh

Padashi²,

Alizadeh³

et al. 2014

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

show abstract

“…Hepatitis B virus and HCV may play a role in the carcinogenesis and the development of extrahepatic malignancies, including PDAC [75][76][77]. Several studies, including several meta-analyses, showed a correlation of HBV infection, including chronic and occult HBV infection, or chronic or inactive HBsAg carries, with increased PDAC risk [78][79][80][81]. According to The Risk Evaluation of Viral Load Elevation and Associated Liver Disease/Cancer-Hepatitis B Virus (REVEAL-HBV) study [82], the association between HBV and PDAC was found in patients with higher viral DNA load (HBV DNA > 300 copies/mL) [82].…”

Section: Gut Microbiome and Its Potential Association With Pdacmentioning

confidence: 99%

The Microbiome as a Potential Target for Therapeutic Manipulation in Pancreatic Cancer

Rahman

Lamarca

Valle

et al. 2021

Cancers

View full text Add to dashboard Cite

Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal cancers and is projected to be the second most common cause of cancer-related death by 2030, with an overall 5-year survival rate between 7% and 9%. Despite recent advances in surgical, chemotherapy, and radiotherapy techniques, the outcome for patients with PDAC remains poor. Poor prognosis is multifactorial, including the likelihood of sub-clinical metastatic disease at presentation, late-stage at presentation, absence of early and reliable diagnostic biomarkers, and complex biology surrounding the extensive desmoplastic PDAC tumour micro-environment. Microbiota refers to all the microorganisms found in an environment, whereas microbiome is the collection of microbiota and their genome within an environment. These organisms reside on body surfaces and within mucosal layers, but are most abundantly found within the gut. The commensal microbiome resides in symbiosis in healthy individuals and contributes to nutritive, metabolic and immune-modulation to maintain normal health. Dysbiosis is the perturbation of the microbiome that can lead to a diseased state, including inflammatory bowel conditions and aetiology of cancer, such as colorectal and PDAC. Microbes have been linked to approximately 10% to 20% of human cancers, and they can induce carcinogenesis by affecting a number of the cancer hallmarks, such as promoting inflammation, avoiding immune destruction, and microbial metabolites can deregulate host genome stability preceding cancer development. Significant advances have been made in cancer treatment since the advent of immunotherapy. The microbiome signature has been linked to response to immunotherapy and survival in many solid tumours. However, progress with immunotherapy in PDAC has been challenging. Therefore, this review will focus on the available published evidence of the microbiome association with PDAC and explore its potential as a target for therapeutic manipulation.

show abstract

“…Nevertheless, several meta-analyses have shown that the PDAC risk positively correlates with HBV infection, particularly for chronic carriers and occult infection (54)(55)(56)(57)(58)(59)(60)(61). However, it is worth to mention that most analyzed studies are coming from Asia and were case-control studies with a heterogeneous design of control group (Table 2).…”

Section: Is Hbv Infection a Risk Factor For Pdac? -Current Evidence Fmentioning

confidence: 99%

Is Hepatitis B Virus a Player in Pancreatic Cancer?

Dumitraşcu¹,

Pineau²

2018

chr

View full text Add to dashboard Cite

Pancreatic cancer (i.e., pancreatic ductal adenocarcinoma, PDAC) is an important healthcare issue and a highly lethal disease. Thus, almost 80% of patients with PDAC will die within one year after diagnosis. Several factors including smoking, obesity, advanced age, diabetes mellitus and chronic pancreatitis have been associated with increased risk of PDAC. Hepatitis B virus (HBV) infection is also considered as a risk factor for PDAC development in some studies. However, the role of HBV infection in PDAC is poorly explored. The present paper reviews the current relevant literature exploring the impact of HBV infection in PDAC. Assessment of HBV infection impact in PDAC is challenging because its effects could be easily underestimated. Indeed, the role played by occult B infection (OBI) and intrinsic difficulties to detect HBV antigens or DNA in pancreatic tissue remains major limitations to further progress. To date a significant proportion of available literature suggests the potential oncogenic role of HBV in PDAC but experimental evidences remain scarce. Remarkably, it appears that HBV infection might influence some clinical and pathological features of patients with PDAC. Future researches to better define the role of HBV infection in developing PDAC are urgently needed.

show abstract

Chronic Hepatitis B Virus Infection and Risk of Pancreatic Cancer: A Meta-analysis

Cited by 25 publications

References 34 publications

Clinical, Laboratory Biomarkers and Imaging Findings of Pancreatic Adenocarcinoma in Iran

Clinical, Laboratory Biomarkers and Imaging Findings of Pancreatic Adenocarcinoma in Iran

The Microbiome as a Potential Target for Therapeutic Manipulation in Pancreatic Cancer

Is Hepatitis B Virus a Player in Pancreatic Cancer?

Contact Info

Product

Resources

About